Kovack Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Kovack Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,638	Closed	-$217K	–	505
2018 Q2	$217K	Buy	+1,638	New	+$154K	0.06%	355

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Kovack Advisors's SRPT Position: Q3 2018 in Review

Kovack Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 1,638 shares — an estimated $217K sold.

Kovack Advisors first reported a position in SRPT in Q2 2018 and held it in 1 quarter. The position peaked at $217K in Q2 2018. 345 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

Kovack Advisors reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
Kovack Advisors sold 1,638 Sarepta Therapeutics shares in Q3 2018, an estimated $217K.
Kovack Advisors first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 1 quarter.
Kovack Advisors's Sarepta Therapeutics position peaked at $217K in Q2 2018.
345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Kovack Advisors's 13F filing for Q3 2018, filed 9 Oct 2018.